Endocrine therapy resistance in ER+ metastatic breast cancer

Nikhil Wagle, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the development of resistance to endocrine therapies and CDK4/6 inhibitors in estrogen receptor-positive (ER+) metastatic breast cancer. Dr Wagle outlines work investigating mechanisms of resistance. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.

• Kategorya